
Sign up to save your podcasts
Or


Special guest Luke Laffin, MD, FACC, the Co-Director, Center for Blood Pressure Disorders with the Department of Cardiovascular Medicine at the Cleveland Clinic joins us to talkabout first-line meds for hypertension.
Listen in as they discuss nuances regarding selection of a first-line medication for the treatment of hypertension.
You’ll also hear practical advice from panelists on TRC’s Editorial Advisory Board:
For the purposes of disclosure, Dr. Luke Laffin reports relevant financial relationships with CRISPR Therapeutics [hyperlipidemia], Eli Lilly [obesity], Medtronic [hypertension] (honorarium); Arrowhead [hyperlipidemia], AstraZeneca [hyperlipidemia], Mineralys Therapeutics [hypertension] (grants/research support).
The other speakers have nothing to disclose. All relevant financial relationships have been mitigated.
TRC Healthcare offers CE credit for this podcast. Log in to your Pharmacist’s Letter or Prescriber Insights account and look for the title of this podcast in the list of available CE courses.
Claim Credit
The clinical resources mentioned during the podcast are part of a subscription to Pharmacist’s Letter and Prescriber Insights:
Send us a text
Email us: [email protected].
The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment.
Find the show on YouTube by searching for ‘TRC Healthcare’ or clicking here.
Learn more about our product offerings at trchealthcare.com.
By TRC Healthcare4.8
3636 ratings
Special guest Luke Laffin, MD, FACC, the Co-Director, Center for Blood Pressure Disorders with the Department of Cardiovascular Medicine at the Cleveland Clinic joins us to talkabout first-line meds for hypertension.
Listen in as they discuss nuances regarding selection of a first-line medication for the treatment of hypertension.
You’ll also hear practical advice from panelists on TRC’s Editorial Advisory Board:
For the purposes of disclosure, Dr. Luke Laffin reports relevant financial relationships with CRISPR Therapeutics [hyperlipidemia], Eli Lilly [obesity], Medtronic [hypertension] (honorarium); Arrowhead [hyperlipidemia], AstraZeneca [hyperlipidemia], Mineralys Therapeutics [hypertension] (grants/research support).
The other speakers have nothing to disclose. All relevant financial relationships have been mitigated.
TRC Healthcare offers CE credit for this podcast. Log in to your Pharmacist’s Letter or Prescriber Insights account and look for the title of this podcast in the list of available CE courses.
Claim Credit
The clinical resources mentioned during the podcast are part of a subscription to Pharmacist’s Letter and Prescriber Insights:
Send us a text
Email us: [email protected].
The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment.
Find the show on YouTube by searching for ‘TRC Healthcare’ or clicking here.
Learn more about our product offerings at trchealthcare.com.

697 Listeners

497 Listeners

105 Listeners

297 Listeners

260 Listeners

3,349 Listeners

1,146 Listeners

730 Listeners

194 Listeners

513 Listeners

427 Listeners

370 Listeners

151 Listeners

3 Listeners

6 Listeners